Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network

Yongqi Zhang,Quanming Yao,Ling Yue,Xian Wu,Ziheng Zhang,Zhenxi Lin,Yefeng Zheng
2023-11-15
Abstract:Accurately predicting drug-drug interactions (DDI) for emerging drugs, which offer possibilities for treating and alleviating diseases, with computational methods can improve patient care and contribute to efficient drug development. However, many existing computational methods require large amounts of known DDI information, which is scarce for emerging drugs. In this paper, we propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs by leveraging the rich information in biomedical networks. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. The different edges on the biomedical network are weighted to indicate the relevance for the target DDI prediction. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.
Quantitative Methods,Artificial Intelligence,Computational Engineering, Finance, and Science,Machine Learning
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: how to accurately predict drug - drug interactions (DDI) between emerging drugs, in order to improve patient care and promote the efficiency of drug development. Since emerging drugs lack a large amount of known DDI information, many existing computational methods are difficult to be directly applied. For this reason, the authors proposed the EmerGNN model, aiming to effectively predict the interactions of emerging drugs by using the rich information in the biomedical network. Specifically, the paper addresses the following key issues: 1. **Data scarcity**: Emerging drugs have limited clinical trial data, resulting in insufficient available DDI information. Traditional methods based on a large amount of known DDI data perform poorly in this situation. 2. **Information integration**: How to effectively integrate relevant information (such as genes, diseases, etc.) in the biomedical network into DDI prediction to make up for the lack of emerging drug data. 3. **Model interpretability**: While predicting DDI, how to make the model highly interpretable in order to better understand the mechanisms behind the prediction results. ### Solution overview The EmerGNN model proposed by the authors solves the above problems in the following ways: - **Graph Neural Network (GNN) architecture**: EmerGNN uses graph neural networks to extract paths from the biomedical network and propagate information through these paths, thereby learning the representations between drug pairs. - **Path extraction and weighting**: By extracting paths connecting drug pairs and weighting different relationships on the paths, the information relevant to the target DDI prediction is emphasized. - **Bidirectional information flow**: EmerGNN considers not only the information transfer from one drug to another but also the reverse information flow, in order to more comprehensively capture the interactions between drugs. - **Attention mechanism**: The attention mechanism is introduced to adjust the importance of the edges on the paths, enabling the model to focus on the most relevant biomedical concepts. Through these methods, EmerGNN can more accurately predict DDI between emerging drugs in the case of data scarcity and has high interpretability. ### Experimental verification The paper verifies the effectiveness of EmerGNN through multiple experiments, including: - Performance comparison on two public datasets, DrugBank and TWOSIDES. - Comparison with multiple baseline methods, demonstrating the superior performance of EmerGNN under different task settings. - Model complexity analysis, proving the rationality of EmerGNN in terms of computational efficiency and parameter usage. In summary, this paper proposes an innovative deep - learning method that can effectively address the challenges in DDI prediction of emerging drugs and provides strong support for drug development and clinical applications.